ObjectiveThe purpose of this review was to evaluate the role of community pharmacists
in provision of screening with/without subsequent management of undiagnosed
chronic obstructive pulmonary disease (COPD) and uncontrolled asthma.MethodsAn extensive literature search using four databases (ie. Medline, PubMed,
International Pharmaceutical Abstracts (IPA) and Scopus) with search terms
pharmacy, screening, asthma or COPD was conducted. Searches were limited to
the years 2003-2013, those in English and those reporting research with
humans. Data retrieval, analysis and result presentation employed a scoping
review method.ResultsSeventeen articles met the inclusion/exclusion criteria, of which fifteen
studies were based on people with asthma and two were based on people with
COPD. Only seven asthma studies and one COPD study involved screening
followed by subsequent management. More than half of the people screened
were found to be poorly controlled and up to 62% of people were identified
at high risk for COPD by community pharmacists. The studies varied in the
method and type of asthma control assessment/screening, the type of
intervention provided and the outcomes measured. The limitations of the
reviewed studies included varying definitions of asthma control, different
study methodologies, and the lack of long-term follow-up. While many
different methods were used for risk assessment and management services by
the pharmacists, all the studies demonstrated that community pharmacists
were capable of identifying people with poorly controlled asthma and
undiagnosed COPD and providing them with suitable interventions.ConclusionsThe literature review identified that community pharmacists can play an
effective role in screening of people with poorly controlled asthma and
undiagnosed COPD along with delivering management interventions. However,
there is very little literature available on screening for these chronic
respiratory conditions. Future research should focus on development of
patient care delivery model incorporating a screening protocol followed by
targeted management interventions delivered by the community pharmacist.